A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
NCT07652047
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Obesity & Overweight
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 55 years
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Corxel Pharmaceuticals
- Last updated on ClinicalTrials.gov
- June 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Nevada · 1
- Corxel Investigational site · Las Vegas, NV
Texas · 1
- Corxel Investigational Site · Austin, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.